AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. QNRX
  4. [DEF 14A] Quoin Pharmaceuticals, Ltd. American Definitive Proxy Statement

[DEF 14A] Quoin Pharmaceuticals, Ltd. American Definitive Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
DEF 14A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock QNRX logo
Quoin Pharmaceuticals Ltd

NASDAQ:QNRX

QNRX Rankings

#10808 Ranked by Market Cap
N/A Ranked by Dividends

QNRX Latest News

Aug 7, 2025
Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update
Jul 31, 2025
Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Jul 29, 2025
Quoin Pharmaceuticals Provides Product Portfolio Update
Jun 26, 2025
Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases
Jun 24, 2025
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

QNRX Latest SEC Filings

Jul 8, 2025
[8-K] Quoin Pharmaceuticals, Ltd. American Reports Material Event
Jul 7, 2025
[PRE 14A] Quoin Pharmaceuticals, Ltd. American Preliminary Proxy Statement
Jun 25, 2025
[8-K] Quoin Pharmaceuticals, Ltd. American Reports Material Event
Jun 20, 2025
[8-K] Quoin Pharmaceuticals, Ltd. American Reports Material Event

QNRX Stock Data

4.26M
546.54k
7.08%
6.86%
1.56%
Biotechnology
Pharmaceutical Preparations
United States
KFAR SABA